Psilocybin therapy with Zolpidem

Small molecule

Psilocybin therapy with Zolpidem is one of 46 small molecule programs targeting Low back pain. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Low Back PainPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Sympazan

Lundbeck

Phase 3

1 2

Tofranil

Sanofi

Phase 3

1 3

Arcoxia

Novartis

Phase 3

1 4

Suboxone

IIndivior Inc.

Phase 3

4 5

Pred Forte

Novartis

Phase 3

—6

Keterol

PPamukkale University

Phase 3

3 7

Tylenol

KKenvue Brands

Phase 3

3 8

Anjeso

Boehringer Ingelheim

Phase 3

1 9

Tanezumab

Pfizer

Phase 3

4 10

Xylocaine

MMEDRx USA, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low back pain1 trial

Psilocybin Therapy for Chronic Low Back Pain

Recruiting·JJoshua Woolley, MD, PhD·Phase 1/2·NCT05351541·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Psilocybin therapy with Zolpidem. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybin therapy with Zolpidem compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybin therapy with Zolpidem. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joshua Woolley, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJoshua Woolley, MD, PhD

Psilocybin therapy with Zolpidem

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Low back pain1 trial

References

Drug Info

Quick Facts

Related News